Bastide Le Confort Médical SA provided revenue guidance for the first half of 2022. At the end of the first half of 2021/2022, the Group reconfirms its revenue target of 460 million on a like-for-like basis, with an operating margin before non-recurring items of more than 8.3%, taking into account the favorable evolution of the product mix and despite price cuts in Respiratory (sleep apnea) and Diabetes services.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.1 EUR | 0.00% |
|
+11.05% | -25.00% |
05-15 | BASTIDE LE CONFORT MEDICAL : De facto maintained guidance; more disposals to propel debt reduction | ![]() |
05-15 | Bastide: 8.2% increase in quarterly sales | CF |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.00% | 161M | |
+2.30% | 3.18B | |
+26.80% | 2.11B | |
0.00% | 1.91B | |
+70.62% | 714M | |
-16.52% | 433M | |
-13.84% | 132M | |
+1.92% | 67.84M |
- Stock Market
- Equities
- BLC Stock
- News Bastide Le Confort Médical
- Bastide Le Confort Médical SA Provides Revenue Guidance for the First Half of 2022